Ionis Pharmaceuticals Inc IONS
Deals with insiders in the proxy filed Apr 23, 2026
Proxy, Item 404Deals between IONS and its directors, executives, owners of more than 5% or their families: a relative on the payroll, a plane the company charters from its CEO, a director's company that buys from it. SEC rules (Item 404) make the company list every such deal over $120,000 in its proxy statement.
New this year
Compared with Apr 25, 2025
Paragraphs about a deal, a person or a relative with nothing like them in the proxy filed Apr 25, 2025.
Certain Relationships and Related Transactions“Mariana Baroldi is an Executive Director in our Corporate Operations department and the wife of Joseph T. Baroldi, EVP and Chief Business Officer. We reviewed Ms. Baroldi’s compensation and determined it is within the range that we target for other employees at the same level at Ionis. Ms. Baroldi’s total compensation for fiscal year 2025 was $632,709, consisting of salary, bonuses, equity awards, and all other compensation.”
Read it in the proxyopen_in_new
Certain Relationships and Related Transactions“One of our directors, Joseph Wender, is a Senior Consultant to Goldman Sachs & Co. (“Goldman”), a firm we engage from time to time for investment banking services. We paid Goldman an aggregate amount of approximately $448,000 in 2025, which is substantially less than 5% of Goldman’s gross revenues for its 2025 fiscal year.”
Read it in the proxyopen_in_new
Certain Relationships and Related Transactions“One of our directors, Joseph Loscalzo, is a Hersey Distinguished Professor of the Theory and Practice of Medicine, the Samuel A. Levine Professor of Medicine at Harvard Medical School and Physician-in-Chief Emeritus at Brigham and Women’s Hospital, which we engage from time to time for clinical research support services. We paid Brigham and Women’s Hospital an aggregate amount of approximately $3.1 million in 2025, which is substantially less than 5% of Mass General Brigham’s gross revenues for its 2025 fiscal year. Mass General Brigham is the integrated health care system of which Brigham and Women’s Hospital is a part.”
Read it in the proxyopen_in_new
Certain Relationships and Related Transactions“In late 2019, the n-Lorem Foundation, a non-profit organization, was formed to provide advanced, experimental RNA-targeted medicines free of charge for life to patients living with ultra-rare diseases. The n-Lorem Foundation was established with an initial investment by our former Executive Chairman of the Board and Chief Executive Officer, Dr. Stanley Crooke, and his wife, Dr. Rosanne Crooke. Prior to 2022, the Company made cash donations to n-Lorem. Ms. Parshall, one of the Company’s non-employee directors, also serves as a director for the n-Lorem Foundation. Additionally, Dr. Geary, who served as our EVP, Chief Development Officer until December 2025, serves as a director for the n-Lorem Foundation. None of our executive officers or directors is compensated for service to the n-Lorem Foundation.”
Read it in the proxyopen_in_new
No longer reported 2 paragraphs of the proxy filed Apr 25, 2025 with nothing like them this year
Policies and Procedures Regarding Related Party Transactions“The following table is being provided pursuant to Item 402(x)(2) of Regulation S-K:”
Read it in last year's proxyopen_in_new
Policies and Procedures Regarding Related Party Transactions“securities price of the fair value of closing market price of trading day ending”
Read it in last year's proxyopen_in_new
New wording of the review policy 3 paragraphs without an amount or a name
Certain Relationships and Related Transactions“We have provided some of the information below because you may find it useful when evaluating the proposals contained in this Proxy Statement. When we include a transaction in this section, we do not necessarily mean that the transaction qualifies as a related party transaction under the securities laws.”
Read it in the proxyopen_in_new
Certain Relationships and Related Transactions“We have entered into indemnity agreements with each of our executive officers and directors and certain non-executive officers which provide, among other things, that we will indemnify such officer or director, under the circumstances and to the extent provided for therein, for expenses, damages, judgments, fines and settlements they may be required to pay in actions or proceedings which they are or may be made a party by reason of their position as a director, officer or other agent of Ionis, and otherwise to the fullest extent permitted under Delaware law and our bylaws. Our bylaws provide that we will indemnify our directors and executive officers to the fullest extent not prohibited by Delaware law or any other applicable law, except that we will generally not be required to indemnify a director or executive officer in connection with any proceeding initiated by such director or executive officer.”
Read it in the proxyopen_in_new
Policies and Procedures Regarding Related Party Transactions“For calendar year 2025, there were no items to disclose pursuant to Item 402(x)(2) of Regulation S-K.”
Read it in the proxyopen_in_new
The whole section
As filed
12 paragraphs quoted as filed
Certain Relationships and Related Transactions“We have provided some of the information below because you may find it useful when evaluating the proposals contained in this Proxy Statement. When we include a transaction in this section, we do not necessarily mean that the transaction qualifies as a related party transaction under the securities laws.”
Read it in the proxyopen_in_new
Certain Relationships and Related Transactions“Mariana Baroldi is an Executive Director in our Corporate Operations department and the wife of Joseph T. Baroldi, EVP and Chief Business Officer. We reviewed Ms. Baroldi’s compensation and determined it is within the range that we target for other employees at the same level at Ionis. Ms. Baroldi’s total compensation for fiscal year 2025 was $632,709, consisting of salary, bonuses, equity awards, and all other compensation.”
Read it in the proxyopen_in_new
Certain Relationships and Related Transactions“One of our directors, Joseph Wender, is a Senior Consultant to Goldman Sachs & Co. (“Goldman”), a firm we engage from time to time for investment banking services. We paid Goldman an aggregate amount of approximately $448,000 in 2025, which is substantially less than 5% of Goldman’s gross revenues for its 2025 fiscal year.”
Read it in the proxyopen_in_new
Certain Relationships and Related Transactions“One of our directors, Joseph Loscalzo, is a Hersey Distinguished Professor of the Theory and Practice of Medicine, the Samuel A. Levine Professor of Medicine at Harvard Medical School and Physician-in-Chief Emeritus at Brigham and Women’s Hospital, which we engage from time to time for clinical research support services. We paid Brigham and Women’s Hospital an aggregate amount of approximately $3.1 million in 2025, which is substantially less than 5% of Mass General Brigham’s gross revenues for its 2025 fiscal year. Mass General Brigham is the integrated health care system of which Brigham and Women’s Hospital is a part.”
Read it in the proxyopen_in_new
Certain Relationships and Related Transactions“In late 2019, the n-Lorem Foundation, a non-profit organization, was formed to provide advanced, experimental RNA-targeted medicines free of charge for life to patients living with ultra-rare diseases. The n-Lorem Foundation was established with an initial investment by our former Executive Chairman of the Board and Chief Executive Officer, Dr. Stanley Crooke, and his wife, Dr. Rosanne Crooke. Prior to 2022, the Company made cash donations to n-Lorem. Ms. Parshall, one of the Company’s non-employee directors, also serves as a director for the n-Lorem Foundation. Additionally, Dr. Geary, who served as our EVP, Chief Development Officer until December 2025, serves as a director for the n-Lorem Foundation. None of our executive officers or directors is compensated for service to the n-Lorem Foundation.”
Read it in the proxyopen_in_new
Certain Relationships and Related Transactions“We have entered into indemnity agreements with each of our executive officers and directors and certain non-executive officers which provide, among other things, that we will indemnify such officer or director, under the circumstances and to the extent provided for therein, for expenses, damages, judgments, fines and settlements they may be required to pay in actions or proceedings which they are or may be made a party by reason of their position as a director, officer or other agent of Ionis, and otherwise to the fullest extent permitted under Delaware law and our bylaws. Our bylaws provide that we will indemnify our directors and executive officers to the fullest extent not prohibited by Delaware law or any other applicable law, except that we will generally not be required to indemnify a director or executive officer in connection with any proceeding initiated by such director or executive officer.”
Read it in the proxyopen_in_new
Policies and Procedures Regarding Related Party Transactions“A committee of the Board composed entirely of independent directors approves transactions with related persons, as defined under SEC regulations. The Compensation Committee approves all compensation we pay to employees who may qualify as related persons, and the Nominating, Governance and Review Committee approves all other related party transactions, as specified in its charter.”
Read it in the proxyopen_in_new
Policies and Procedures Regarding Related Party Transactions“For transactions that do not qualify as related party transactions, but may otherwise present a conflict of interest, our Code of Ethics and Business Conduct requires the Nominating, Governance and Review Committee (for our executive officers and directors) or the Chief Executive Officer or Chief Legal Officer (for non-executive officers and non-directors) to determine whether a conflict of interest exists.”
Read it in the proxyopen_in_new
Policies and Procedures Regarding Related Party Transactions“Our written policies and procedures specifically prohibit personal loans to our executive officers and any employee with a title of Vice President or higher.”
Read it in the proxyopen_in_new
Policies and Procedures Regarding Related Party Transactions“Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic information From time to time, the Company grants stock options to its employees, including the named executive officers. Each year, all current employees receive a stock option grant on the first business day of the year in recognition of their performance in the preceding year. In addition, all new hires receive a stock option grant on their date of hire. Employees who are promoted receive a stock option grant on the date of such employee’s promotion.”
Read it in the proxyopen_in_new
Policies and Procedures Regarding Related Party Transactions“Non-employee directors receive automatic grants of initial and annual stock option awards at the time of a director’s initial appointment or election to the board and on July 1 of each year, respectively, pursuant to the Non-Employee Directors’ Stock Option Plan. In addition to regular, predetermined grants of stock options to employees as discussed above, non-employee directors receive option grants on the regular, predetermined grant dates pursuant to the Non-Employee Directors’ Stock Option Plan. The grants to employees and non-employee directors occur regardless of whether there is any material nonpublic information (“ The Company does not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments with option-like features. Furthermore, the Company has not timed the release of MNPI for the purpose of affecting the value of executive compensation.”
Read it in the proxyopen_in_new
Policies and Procedures Regarding Related Party Transactions“For calendar year 2025, there were no items to disclose pursuant to Item 402(x)(2) of Regulation S-K.”
Read it in the proxyopen_in_new
Paragraphs are compared by their words, not read by AI: one counts as new when no paragraph last year shares half of its words, or when it names a person or company last year's section did not. A deal reported again with a new amount is not new. Always check the filing. Open the proxy ↗ · Last year's proxy ↗
Sources
The related-party section (Item 404) of the latest annual proxy statement (DEF 14A), against last year's, compared by their words.
Also
CEO pay: the same proxy's pay versus performance table.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IONS/export.csv") into a cell.